Does lower blood pressure reduce CV events in patients at intermediate risk? Probably not.
Bottom line: Blood pressure-lowering treatment with candesartan and HCTZ in a population at intermediate CV risk without known CV disease did not affect CV morbidity and mortality.Review and summary of: Lonn EM, Bosch J, Lopez-Jaramillo P, et al. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016; 374(21):2009-2020.
Evidence-based practice 20, no. 3 (2017): E8